



FOR IMMEDIATE RELEASE:

MEDIA CONTACTS:

Misha Plam, Ph.D. Founder and CEO BiOptix, Inc. 1745 38th Street, Suite A Boulder CO 80301, misha@bioptix.com 303.641 3669	
---	--

BiOptix Unveils Label-free, Highly-sensitive Microarray BioAnalyzer

Offering delivers unique value across diagnostic, clinical and research audiences

BOULDER, CO, December 1, 2008 /PRNewswire/ - BiOptix, Inc. has unveiled a best-in-class commercially available microarray bio-analyzer, model 207B, which incorporates novel, highly-sensitive and label-free technology invented by John Hall, 2005 Nobel Prize Laureate, yielding reliable and real-time molecular interaction detection and measurement of kinetic constants capabilities. The BiOptix 207B has demonstrated sensitivity 10 times greater than the current commercially available competing technologies while additionally enabling superior fixed and expandable multiplexing capabilities compared to competitive offerings.

The BiOptix 207B sensor array format enables simultaneous affinity measurements of a diverse array of analytes such as oligonucleotides, antibodies, bacteria, viruses, glycans and other proteins as well as identification and correction of bulk and non-specific binding effects delivered with industry leading sensitivity. Applications for the BiOptix 207B include pharmaceutical quality control, research and development, biotherapeutic drug discovery, rapid point-of-care diagnostics, and environmental monitoring. The instrument features a small footprint, low power consumption, and user-friendly interface.



About: BiOptix develops ultra-sensitive biosensors for detection of clinically significant trace amounts of biological and chemical agents in real-time and with minimal human intervention. The biosensor design relies upon the common path interferometric detection principle in combination with non-resonant surface plasmon excitation. This design was conceived by BiOptix Chief Scientific Adviser, Dr. John Hall, 2005 Physics Nobel Prize Laureate.

###